UiPath
PATH
$11.68
-1.02%
UiPath Inc. provides an end-to-end enterprise automation platform, leveraging robotic process automation (RPA), computer vision, and AI to automate repetitive tasks across industries. As a pioneer and market leader in the RPA space, UiPath has established a strong competitive position with a comprehensive platform that spans automation, AI, and API integration. The current investor narrative centers on UiPath's transition from a pure-play RPA provider to an AI-driven automation leader, with recent strong Q1 results and a raised outlook fueling optimism that revenue growth is finally translating into sustainable profitability. However, debates persist around the threat from generative AI and the company's ability to maintain its competitive edge.…
PATH
UiPath
$11.68
Related headlines
Investment Opinion: Should I buy PATH Today?
Rating: Hold. UiPath is a speculative growth stock with improving fundamentals but faces existential competitive threats. The analyst consensus is neutral (1 Buy, 3 Hold, 1 Underperform), and the implied target price of ~$13.55 based on forward P/E of 12.9x and average EPS estimate of $1.05 offers 16% upside.
Supporting evidence: Revenue growth accelerated to 13.6% YoY in Q4 FY2026, net margin improved to 21.7%, and free cash flow is $352.2M TTM. The forward P/E of 12.9x is a 48% discount to the software industry average of 25x. However, the trailing P/E of 24.2x is only a 19% discount, indicating the market expects significant earnings growth to justify the forward multiple.
Risks & Conditions: The biggest risks are generative AI disruption and the weak analyst consensus. This Hold would upgrade to Buy if the stock breaks above its 52-week high of $19.84 or if revenue growth consistently exceeds 15%. It would downgrade to Sell if revenue growth decelerates below 10% or if the stock breaks below $9.20. Valuation verdict: UiPath appears undervalued on a forward P/E basis relative to peers and its own history, but the discount is warranted by competitive risks.
Sign up to view all
PATH 12-Month Price Forecast
UiPath's improving fundamentals are offset by significant competitive threats from generative AI and a lack of analyst conviction. The stock's low forward P/E suggests the market is already pricing in risks, but a catalyst is needed to break the downtrend. The base case of range-bound trading is most likely, but a bullish breakout could occur if the company demonstrates AI leadership. The neutral stance reflects balanced risk/reward with a slight positive tilt given the valuation discount.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UiPath's 12-month outlook, with a consensus price target around $15.18 and implied upside of +30.0% versus the current price.
Average Target
$15.18
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$9 - $15
Analyst target range
UiPath is covered by 5 analysts, with a consensus recommendation leaning neutral. The distribution includes 1 Buy, 3 Hold, and 1 Underperform, indicating a cautious stance. The average estimated EPS for the next fiscal year is $1.05, with a range of $1.04 to $1.06. The average revenue estimate is $2.07 billion, implying a growth rate of approximately 13% from the trailing twelve months. The consensus target price is not explicitly provided, but based on the forward P/E of 12.9x and the average EPS estimate of $1.05, the implied target price is around $13.55, representing approximately 16% upside from the current price of $11.68. The target range is not explicitly given, but the low EPS estimate of $1.04 and high of $1.06 suggest a narrow range, indicating relatively high conviction among analysts. Recent ratings from institutional firms show a mix of Hold/Neutral ratings, with only Canaccord Genuity maintaining a Buy. B of A Securities has an Underperform rating, reflecting bearish sentiment. The wide dispersion in ratings (from Buy to Underperform) suggests high uncertainty about the company's future. The lack of a strong bullish consensus implies that the stock may face headwinds in gaining upward momentum without a clear catalyst.
Bulls vs Bears: PATH Investment Factors
UiPath presents a compelling risk/reward with accelerating revenue growth, strong profitability, and a clean balance sheet, yet faces existential threats from generative AI and lacks strong analyst support. The bull case rests on the company's transition to an AI-driven automation leader and its attractive forward valuation (12.9x P/E). The bear case centers on competitive disruption and the stock's persistent downtrend. The single most important tension is whether UiPath can maintain its competitive edge against generative AI—if it does, the stock could re-rate significantly; if not, growth could stall and valuation could compress further.
Bullish
- Accelerating Revenue Growth: Q4 FY2026 revenue grew 13.6% YoY to $481.1M, accelerating from 8.8% in Q4 FY2025 and 8.4% in Q3 FY2026. This indicates UiPath's platform is gaining traction, particularly in AI-driven automation.
- Sustainable Profitability Achieved: Net income of $104.5M in Q4 FY2026 versus a loss of $22.6M a year ago, with net margin of 21.7%. Operating margin improved to 16.7% from 7.9%, demonstrating strong operating leverage.
- Fortress Balance Sheet: Zero debt (debt-to-equity 0.039) and current ratio of 2.48 provide ample liquidity. Free cash flow of $352.2M TTM funds growth without external financing.
- Attractive Forward Valuation: Forward P/E of 12.9x is a steep discount to the software industry average of 25x and to UiPath's own trailing P/E of 24.2x. This implies the market is not fully pricing in expected earnings growth.
Bearish
- Generative AI Disruption Threat: Generative AI could commoditize RPA, reducing UiPath's competitive moat. Recent news highlights existential competition from AI that could permanently impair growth trajectory.
- Weak Analyst Consensus: Only 1 Buy, 3 Hold, and 1 Underperform among 5 analysts. B of A Securities has an Underperform rating, reflecting bearish sentiment and high uncertainty.
- Significant Price Decline: Stock is down 26.4% YTD and 9.4% over 1 year, underperforming the S&P 500 by 30% over 1 year. The 52-week range of $9.20-$19.84 shows the stock near the bottom.
- High Short Interest: Short ratio of 2.64 indicates elevated bearish positioning. This could lead to volatility but also reflects skepticism about the company's growth sustainability.
PATH Technical Analysis
UiPath is in a sustained downtrend over the past year, with a 1-year price change of -9.39% and a 52-week range of $9.20 to $19.84. The current price of $11.68 sits at approximately 22% of the 52-week range (from the low), indicating the stock is near the lower end of its annual range. This positioning suggests the market has priced in significant pessimism, but also leaves room for a potential recovery if fundamentals improve. The stock's beta of 0.974 indicates volatility roughly in line with the S&P 500, providing no additional cushion against market swings. Short-term momentum shows a conflicting picture: the 1-month price change is +8.65%, while the 3-month change is +24.52%, both positive and contrasting with the negative 1-year trend. This divergence could signal a potential trend reversal or a temporary mean-reversion bounce within a broader downtrend. The recent rally from the 52-week low of $9.20 (reached in April 2026) to $11.68 represents a 27% gain, suggesting buying interest at lower levels. The 52-week high of $19.84 serves as key resistance; a breakout above this level would signal a major trend reversal. Conversely, a breakdown below the 52-week low of $9.20 would indicate further downside and potential acceleration of the downtrend. The stock's beta near 1.0 implies that it moves in line with the market, so broader market direction will be an important factor for the stock's near-term trajectory.
Beta
0.97
0.97x market volatility
Max Drawdown
-51.4%
Largest decline past year
52-Week Range
$9-$20
Price range past year
Annual Return
-9.4%
Cumulative gain past year
| Period | PATH Return | S&P 500 |
|---|---|---|
| 1m | +8.7% | +1.8% |
| 3m | +24.5% | +10.0% |
| 6m | -28.4% | +8.8% |
| 1y | -9.4% | +21.1% |
| ytd | -26.4% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PATH Fundamental Analysis
UiPath's revenue trajectory is accelerating, with the most recent quarterly revenue (Q4 FY2026, ended January 31, 2026) reaching $481.1 million, a 13.6% year-over-year increase. This marks an acceleration from the prior quarter's revenue of $411.1 million (Q3 FY2026) and from the 8.8% growth seen in Q4 FY2025. The growth is driven by subscription services ($251.2 million) and license revenue ($215.9 million), while professional services contribute a smaller portion. The accelerating growth suggests that UiPath's platform is gaining traction, particularly in the AI and automation space, which supports the investment case for a growth reacceleration. UiPath has achieved profitability, with net income of $104.5 million in Q4 FY2026, compared to a net loss of $22.6 million in the same quarter last year. Gross margin remains strong at 84.9%, reflecting the software nature of the business. Operating margin improved to 16.7% in Q4 FY2026, up from 7.9% in the prior year, indicating operating leverage. The company's net margin of 21.7% is healthy and above the industry average for software companies, demonstrating that the business model is generating sustainable profits. UiPath maintains a fortress balance sheet with zero debt (debt-to-equity ratio of 0.039) and a current ratio of 2.48, indicating ample liquidity. Free cash flow for the trailing twelve months is $352.2 million, providing strong internal funding for growth initiatives. The company's ROE of 13.6% is solid, reflecting efficient use of equity capital. The strong cash position and positive free cash flow generation mean UiPath does not rely on external financing, reducing financial risk.
Quarterly Revenue
$481107000.0B
2026-01
Revenue YoY Growth
+13.56%
YoY Comparison
Gross Margin
84.88%
Latest Quarter
Free Cash Flow
$352160000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PATH Overvalued?
Since UiPath has positive net income, the P/E ratio is the primary valuation metric. The trailing P/E is 24.2x, while the forward P/E is 12.9x, implying that the market expects significant earnings growth in the coming year. The large gap between trailing and forward P/E suggests that the market is pricing in a sharp earnings recovery, which aligns with the recent profitability improvements. Compared to the software industry average P/E of approximately 30x, UiPath's trailing P/E of 24.2x represents a 19% discount. However, the forward P/E of 12.9x is a steep discount to the industry average forward P/E of 25x, implying the market is not fully pricing in the expected growth. This discount may be justified by the competitive threats from generative AI and the company's historical volatility, but it also presents a potential value opportunity if the growth trajectory continues. Historically, UiPath's trailing P/E has ranged from negative (when unprofitable) to as high as 994x in Q2 FY2026. The current trailing P/E of 24.2x is near the lower end of its historical range, suggesting that the stock is not expensive relative to its own history. The forward P/E of 12.9x is even more compelling, indicating that the market is pricing in a significant earnings rebound. This low valuation relative to history could be interpreted as a value opportunity, but it also reflects the market's skepticism about the sustainability of the company's growth and profitability.
PE
24.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -163x~994x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
50.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: UiPath's financials are solid with zero debt and positive free cash flow, but the company's growth acceleration to 13.6% YoY may not be sustainable if competition intensifies. The net margin of 21.7% is healthy, but operating margin of 16.7% could compress if the company increases spending to defend market share. Revenue concentration in subscription and license fees (97% of total) makes the model resilient, but any slowdown in new customer additions would directly impact growth.
Market & Competitive Risks: The primary external threat is generative AI, which could render traditional RPA obsolete. UiPath's beta of 0.974 indicates market-like volatility, so a broad market downturn would pressure the stock. The stock's 26.4% YTD decline versus the S&P 500's 10.7% gain shows severe relative underperformance, suggesting sector rotation away from growth stocks. Recent news about Nvidia's $26B AI investment highlights the massive capital flowing into AI, which could overshadow UiPath's platform.
Worst-Case Scenario: If generative AI disrupts RPA demand and UiPath fails to adapt, revenue growth could decelerate below 10%, leading to multiple compression. The 52-week low of $9.20 represents a 21% downside from the current price of $11.68. In a severe scenario, the stock could revisit its all-time low of $9.20 or lower, implying a potential loss of 21% or more. Historical max drawdown of -51.37% suggests the stock is capable of significant declines.
FAQ
The primary risk is generative AI disruption, which could commoditize RPA and impair UiPath's growth trajectory. Second, the weak analyst consensus (only 1 Buy) and high short ratio of 2.64 indicate significant bearish sentiment. Third, the stock's beta of 0.974 means it moves in line with the market, so a broad downturn would pressure the price. Finally, the stock is down 26.4% YTD and 9.4% over 1 year, showing persistent negative momentum. The most severe risk is a 21% decline to the 52-week low of $9.20 if growth disappoints.
The base case (50% probability) expects the stock to trade in a range of $11-$14 over the next 12 months, assuming 10-13% revenue growth and stable margins. The bull case (25% probability) targets $15-$20 if UiPath successfully navigates the AI transition and revenue accelerates above 15%. The bear case (25% probability) sees the stock falling to $8-$10 if generative AI disrupts demand. The most likely scenario is the base case, with the stock remaining range-bound until a clear catalyst emerges. The implied analyst target of ~$13.55 aligns with the upper end of the base case.
UiPath appears undervalued on a forward P/E basis at 12.9x, compared to the software industry average of 25x and its own trailing P/E of 24.2x. The large gap between trailing and forward P/E implies the market expects significant earnings growth, which is supported by the recent profitability improvement. However, the discount is justified by competitive risks from generative AI and the stock's persistent downtrend. Relative to its own history, the current P/E is near the lower end, suggesting the stock is not expensive. Overall, UiPath is likely undervalued if growth sustains, but fairly valued if risks materialize.
UiPath offers a compelling risk/reward with a forward P/E of 12.9x, a 48% discount to the software industry average, and accelerating revenue growth of 13.6% YoY. However, the stock faces existential threats from generative AI and has a weak analyst consensus (only 1 Buy out of 5). For aggressive growth investors with a long-term horizon, it could be a good buy if they believe UiPath will successfully integrate AI. For conservative investors, the risks likely outweigh the potential upside. The implied analyst target of ~$13.55 offers 16% upside, but the stock's 26.4% YTD decline highlights significant downside risk.
UiPath is better suited for long-term investment given its speculative nature and high volatility. The stock's beta of 0.974 and 26.4% YTD decline make it risky for short-term trading, though the recent 8.7% one-month gain shows potential for tactical moves. The company's accelerating revenue growth and strong balance sheet support a long-term thesis, but the generative AI threat requires a multi-year view to play out. A minimum holding period of 3-5 years is recommended to allow the company to execute its AI strategy. Short-term traders should focus on earnings events and technical levels like $9.20 support and $12.50 resistance.